BioTuesdays

Category - Markets

Dawson James starts Fortress Biotech at buy; PT $19

Dawson James Securities launched coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and price target of $19. The stock closed at $6.51 on Aug. 23. “Creating a launch pad for biotechnology assets, Fortress...

HCW starts Sangamo Therapeutics at buy; PT $16

H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the prevailing view on...

Athersys Logo

Dawson James starts Athersys at buy; PT $11

Dawson James Securities launched coverage of Athersys (NASDAQ:ATHX) with a “buy” rating and $11 price target. The stock closed at $1.40 on Aug. 23. “Athersys has the potential to change the treatment paradigm for...

INmune Bio

HCW starts INmune Bio at buy; PT $11.50

H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...

HCW starts Targovax ASA at buy; PT 19 NOK

H.C. Wainwright initiated coverage of Oslo-based Targovax ASA (OSE:TRVX) with a “buy” rating and price target of 19 NOK. The stock closed at 5.44 NOK on Aug. 19. Analyst Joseph Pantginis writes that Targovax’s lead...

Synlogic

BTIG cuts Synlogic PT to $9 from $22

BTIG reduced its price target for Synlogic (NASDAQ:SYBX) to $9 from $22 after the company discontinued development of SYNB1020, an early-stage clinical product candidate for the treatment of hyperammonemia. The stock...

Scynexis Logo

Brookline starts SCYNEXIS at buy; PT $5

Brookline Capital Markets launched coverage of SCYNEXIS (NASDAQ:SCYX) with a “buy” rating and $5 price target. The stock closed at $1.07 on Aug. 19. Analyst Kumaraguru Raja writes that SCYNEXIS’ lead product candidate...

HCW starts Entasis Therapeutics at buy; PT $18

H.C. Wainwright initiated coverage of Entasis Therapeutics (NASDAQ:ETTX) with a “buy” rating and $18 price target. The stock closed at $8.25 on Aug. 16. Spun out of AstraZeneca in 2015, Entasis is focused on novel...